ATACAND HCT Rx
Generic Name and Formulations:
Candesartan cilexetil, hydrochlorothiazide; 16mg/12.5mg, 32mg/12.5mg, 32mg/25mg; scored tabs.
Indications for ATACAND HCT:
Not for initial therapy. May be substituted for titrated components. BP not controlled on HCTZ 25mg once daily, or controlled but serum potassium decreased: one Atacand HCT 16/12.5mg tab once daily. BP not controlled on candesartan 32mg per day: initially one Atacand HCT 32/12.5mg tab once daily; may increase to 32/25mg once daily. Moderate-to-severe hepatic impairment or CrCl ≤30mL/min: not recommended.
Anuria. Sulfonamide allergy. Concomitant aliskiren in patients with diabetes.
Fetal toxicity may develop; discontinue if pregnancy is detected. Correct hypovolemia before starting, or monitor closely. Hepatic or renal impairment. Renal artery stenosis. CHF. Asthma. Diabetes. SLE. Gout. Surgery. Acute myopia. Secondary angle-closure glaucoma. Hypercalcemia: avoid. Monitor renal function and electrolytes periodically. Elderly. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.
Angiotensin II receptor blocker (ARB) + thiazide diuretic.
See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). Digitalis, lithium toxicity (monitor). Adjust antidiabetic, antigout medications. Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. Hypokalemia with corticosteroids, ACTH. Orthostatic hypotension potentiated by alcohol, CNS depressants. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors; monitor. Potentiates other antihypertensives. May potentiate nondepolarizing muscle relaxants, diazoxide, cyclophosphamide, methotrexate. Concomitant cyclosporine may increase risk of hyperuricemia. Separate dosing by ≥4hrs before or 4–6hrs after cholestyramine or colestipol resins. May antagonize noradrenaline. May interfere with parathyroid tests.
Upper RTI, back pain, dizziness, flu-like symptoms; hypotension, renal dysfunction, electrolyte and metabolic disturbances, rhabdomyolysis (rare).
Sign Up for Free e-newsletters
- Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma
- Is Radioimmunotherapy a Path Forward for Melanoma?
- Handling Chemotherapy Premedications
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|